Arch Biopartners (TSXV:ARCH) Total Assets : C$0.64 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Total Assets?

Arch Biopartners's Total Assets for the quarter that ended in Dec. 2023 was C$0.64 Mil.

During the past 12 months, Arch Biopartners's average Total Assets Growth Rate was -40.30% per year. During the past 3 years, the average Total Assets Growth Rate was 57.50% per year. During the past 5 years, the average Total Assets Growth Rate was -0.80% per year. During the past 10 years, the average Total Assets Growth Rate was 43.20% per year.

During the past 13 years, Arch Biopartners's highest 3-Year average Total Assets Growth Rate was 172.30%. The lowest was -81.50%. And the median was -0.85%.

Total Assets is connected with ROA %. Arch Biopartners's annualized ROA % for the quarter that ended in Dec. 2023 was -346.65%. Total Assets is also linked to Revenue through Asset Turnover. Arch Biopartners's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Arch Biopartners Total Assets Historical Data

The historical data trend for Arch Biopartners's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Total Assets Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Assets

Get a 7-Day Free Trial

0.83

0.74

2.67

0.62

1.17

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															0.72	3.69	1.42	1.17	0.64

Arch Biopartners Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Arch Biopartners's Total Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (A: Sep. 2023 )	+	Total Liabilities (A: Sep. 2023 )
	=	-5.51	+	6.681
	=	1.17

Arch Biopartners's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-5.713	+	6.35
	=	0.64

Arch Biopartners (TSXV:ARCH) Total Assets Explanation

Total Assets is connected with ROA %.

Arch Biopartners's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-3.132	/	( (1.171	+	0.636)	/ 2 )
	=	-3.132	/	0.9035
	=	-346.65 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Arch Biopartners's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (1.171	+	0.636)	/ 2 )
=	0	/	0.9035
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Arch Biopartners Total Assets Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.